PET and MRI Imaging of Brain Tumors Using [18F]PARPi
Pilot Study of [18F]PARPi PET/MR Imaging in Patients With New and/or Suspected Recurrent Brain Tumors
1 other identifier
interventional
5
1 country
1
Brief Summary
This study is to collect data about how 18FPARPi can be used together with PET/positron emission tomography and MRI/magnetic resonance imaging scans to take pictures of brain cancer
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for early_phase_1
Started Nov 2019
Longer than P75 for early_phase_1
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2019
CompletedFirst Submitted
Initial submission to the registry
November 19, 2019
CompletedFirst Posted
Study publicly available on registry
November 21, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 5, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
February 5, 2026
CompletedFebruary 9, 2026
February 1, 2025
6.3 years
November 19, 2019
February 6, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
SUVmax measurements
\[18F\]PARPi updtake in lesions will be quantified by standard SUVmax measurements from PET/MR scans
Up to 24 weeks
Study Arms (1)
Participants with Brain Cancer
EXPERIMENTALParticipants with new or suspected recurrent brain tumors
Interventions
One PET/MR study (with up to 3 scan times) with \[18F\]PARPi
Eligibility Criteria
You may qualify if:
- Patients with new or suspected recurrent brain tumors (including suspected recurrent brain tumors showing growth from any preceding scan)
- Age \>/= 18 years
- Minimum at least one brain lesion size \>/= 1.5cm diameter
- Scheduled to undergo treatment at MSK
- Willingness to sign informed consent
- Able to receive intravenous gadolinium contrast per MSK Department of Radiology guidelines
You may not qualify if:
- Any contraindication to 3T MRI (PET/MR scanner is 4.0 Tesla)
- Pregnancy or breast-feeding women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Robert Young, MD
Memorial Sloan Kettering Cancer Center
Study Design
- Study Type
- interventional
- Phase
- early phase 1
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 19, 2019
First Posted
November 21, 2019
Study Start
November 1, 2019
Primary Completion
February 5, 2026
Study Completion
February 5, 2026
Last Updated
February 9, 2026
Record last verified: 2025-02
Data Sharing
- IPD Sharing
- Will share
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.